Point72 Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$305K	Buy	+13,700	New	+$327K	﹤0.01%	3357
2024 Q3	–	Sell	-102,000	Closed	-$1.66M	–	1938
2024 Q2	$1.66M	Buy	102,000 +12,000	+13%	+$194K	﹤0.01%	1145
2024 Q1	$1.66M	Buy	+90,000	New	+$2.23M	﹤0.01%	1323
2021 Q2	–	Sell	-198,900	Closed	-$5.13M	–	944
2021 Q1	$5.13M	Buy	+198,900	New	+$8.76M	0.02%	560
2018 Q4	–	Sell	-200,000	Closed	-$4.15M	–	927
2018 Q3	$4.15M	Sell	200,000 -1,900,000	-90%	-$29.9M	0.02%	645
2018 Q2	$32.1M	Buy	+2,100,000	New	+$37.4M	0.13%	205
2016 Q4	–	Sell	-120,300	Closed	-$3.83M	–	672
2016 Q3	$3.83M	Buy	+120,300	New	+$4.08M	0.03%	465
2016 Q2	–	Sell	-450,000	Closed	-$12.6M	–	706
2016 Q1	$12.6M	Buy	+450,000	New	+$9.81M	0.1%	245

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Point72 Asset Management's ACAD Position: Q1 2026 in Review

Point72 Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 24% in Q1 2026, selling an estimated $19.1M and leaving 2,577,916 shares worth $57.4M. The position accounts for 0.07% of the portfolio, ranked #317.

Point72 Asset Management first reported a position in ACAD in Q2 2014 and has held it in 38 quarters since. The position peaked at $97.9M in Q1 2018. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Point72 Asset Management held 2,577,916 shares of Acadia Pharmaceuticals worth $57.4M as of Q1 2026.
Point72 Asset Management sold 799,395 Acadia Pharmaceuticals shares in Q1 2026, an estimated $19.1M.
Acadia Pharmaceuticals made up 0.07% of Point72 Asset Management's portfolio in Q1 2026, its #317 holding.
Point72 Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
Point72 Asset Management's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.